Table 1.

Baseline Characteristics Among Eligible Patients

Characteristic	Treatment
	GEM (n = 275)		GEM FDR (n = 277)		GEMOX (n = 272)
	No.	%	No.	%	No.	%
Mean age, years*	63		62		63
Standard deviation	11		11		11
Median	64		61		63
Range	31-88		36-87		29-96
Under 55	57	20.7	88	31.8	59	21.7
55-69	141	51.3	123	44.4	136	50.0
70+	77	28.0	66	23.8	77	28.3
Sex†
Male	155	56.4	160	57.8	124	45.6
Female	120	43.6	117	42.2	148	54.4
Race
Hispanic	9	3.3	12	4.4	12	4.4
Non-Hispanic white	235	85.8	236	86.1	231	85.6
Non-Hispanic black	24	8.8	22	8.0	23	8.5
Other	6	2.2	4	1.5	4	1.5
Previous 6-month weight loss
< 5% of body weight	100	36.6	100	36.8	107	39.8
5-< 10% of body weight	71	26.0	64	23.5	65	24.2
10-< 20% of body weight	78	28.6	79	29.0	65	24.2
20% or more of body weight	24	8.8	29	10.7	32	11.9
Histology grade
Well differentiated	14	5	16	6	22	8
Moderately differentiated	82	30	71	26	56	21
Poorly differentiated/undifferentiated	76	28	77	28	78	29
Missing/unknown	103	38	113	41	116	43
Prior RT
No	254	92.4	253	91.3	250	91.9
Yes	21	7.6	23	8.3	21	7.7
Prior adjuvant chemotherapy
No	260	94.5	259	93.5	261	96.0
Yes	15	5.5	17	6.1	10	3.7
Prior surgery
No	230	83.6	234	84.5	239	87.9
Yes	43	15.6	42	15.2	32	11.8
History of DVT or prior embolus
No	236	85.8	240	86.6	243	89.3
Yes	39	14.2	36	13.0	28	10.3
Disease measurable or not
Measurable only	70	25.5	67	24.2	84	30.9
Nonmeasurable only	13	4.7	13	4.7	16	5.9
Both	192	69.8	194	70.0	172	63.2
PS on study
0	94	34.2	86	31.0	73	26.8
1	147	53.5	157	56.7	168	61.8
2	34	12.4	33	11.9	30	11.0
Disease status on study
Locally advanced	27	9.8	30	10.8	29	10.7
Metastatic	248	90.2	246	88.8	243	89.3
Median CA19-9, U/mL	1,961		1,148		1,077
25%-75% quantile	167-12,024		136-9,651		90-9,301
Median CEA, ng/dL	5.7		5.9		6.3
25%-75% quantile	2.3-30.9		2.4-30.1		2.4-35.5

Abbreviations: GEM, gemcitabine; GEM FDR, gemcitabine fixed-dose rate; GEMOX, gemcitabine 1,000 mg/m²/100 minutes/day 1 plus oxaliplatin 100 mg/m²/day 2 every 14 days; RT, radiotherapy; DVT, deep vein thrombosis; PS, performance status.

^*Age different among three treatment arms, P = .03 (Pearson's χ² test).

^†Sex different among three treatment arms, P < .01 (Pearson's χ² test).